Non-Proliferative Diabetic Retinopathy Market Poised for Strong Growth, Expected to Reach $3.58 Billion by 2028
The Business Research Company's Non-Proliferative Diabetic Retinopathy Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
LANDON, GREATER LANDON, UK, June 20, 2024 /EINPresswire.com/ -- The non-proliferative diabetic retinopathy market1 has experienced robust growth, projected to increase from $2.43 billion in 2023 to $2.62 billion in 2024, with a compound annual growth rate (CAGR) of 7.8%. This growth in the historic period can be attributed to factors such as the increased prevalence of diabetes, aging population, improved awareness, research advancements, lifestyle changes, and enhanced diabetes management.
Surging Prevalence Of Diabetes Fuels Growth In The Non-Proliferative Diabetic Retinopathy Market
The increasing prevalence of diabetes is expected to propel the growth of the non-proliferative diabetic retinopathy market going forward. Diabetes, a chronic metabolic disorder characterized by elevated blood glucose levels due to inadequate insulin production or insulin resistance, is on the rise due to sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. Diabetes leads to non-proliferative diabetic retinopathy by damaging the blood vessels in the retina, primarily due to prolonged high glucose levels in the bloodstream, resulting in vision impairment and potential blindness. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, with projections indicating a rise to 643 million by 2030 and 783 million by 2045. Therefore, the increasing prevalence of diabetes is driving the growth of the non-proliferative diabetic retinopathy market.
Explore the global non-proliferative diabetic retinopathy market with a detailed sample report:
https://www.thebusinessresearchcompany.com/sample_request?id=15620&type=smp
Major Players and Market Trends
Leading companies in the non-proliferative diabetic retinopathy market, such as Pfizer Inc., Johnson & Johnson, and Novartis AG, are focusing on innovations like AI-enabled fundus cameras to enhance diagnostic accuracy and patient outcomes. For example, Optomed's launch of the Optomed Aurora AEYE in May 2024, a handheld AI fundus camera designed to detect more than mild diabetic retinopathy, exemplifies how AI is transforming ophthalmic imaging.
Advancements In AI-Enabled Fundus Cameras For Non-Proliferative Diabetic Retinopathy
Major companies operating in the non-proliferative diabetic retinopathy market are developing AI-enabled cameras to improve patient outcomes and advance the field of ophthalmic imaging. AI-enabled cameras in ophthalmic imaging assist in capturing, analyzing, and interpreting eye images for diagnostic and therapeutic purposes.
Segments:
1. Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2. Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3. End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Region Insights: Asia-Pacific Leading the Market
North America was the largest region in the non-proliferative diabetic retinopathy market in 2023. Asia-Pacific is expected to be the fastest-growing region during the forecast period. Detailed regional dynamics and growth opportunities are explored in the comprehensive report.
Access the complete report for an in-depth analysis of the global non-proliferative diabetic retinopathy market:
https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report
Non-Proliferative Diabetic Retinopathy Global Market Report 2024 from TBRC covers the following information:
• Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Trends, opportunities, strategies and so much more.
The Non-Proliferative Diabetic Retinopathy Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on non-proliferative diabetic retinopathy market size2, non-proliferative diabetic retinopathy market drivers and trends, non-proliferative diabetic retinopathy market major players, competitors' revenues, market positioning, and market growth across geographies. The non-proliferative diabetic retinopathy market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.
Browse Through More Similar Reports By The Business Research Company:
Diabetic Foot Ulcer Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-global-market-report
Proliferative Diabetic Retinopathy (PDR) Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report
Diabetic Gastroparesis Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/diabetic-gastroparesis-treatment-global-market-report
About The Business Research Company3
The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.
Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
X
LinkedIn
1 https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report
2 https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report
3 https://www.thebusinessresearchcompany.com/
![](https://www.einpresswire.com/tracking/article.gif?t=4&a=ewHDCEDt1DshlFzy&i=rKkN_dfAz_Xkf62k)